The cholesterol depleting agent chromium also improves glycemic control in T2DM patients [341], and activates GLUT4 trafficking and insulin-stimulated glucose transport in a cholesterol- and AMPK-dependent manner [342]. Here, SLC2A4 is linked to type 2 diabetes mellitus.